FcRn mediates elongated serum half-life of human IgG in cattle

By Kacskovics Imre   Kis Zsuzsanna   Mayer Balázs   West Anthony P.   Tiangco Noreen E.   Tilahun Mulualem   Cervenak László   Bjorkman Pamela J.   Goldsby Richard A.   Szenci Ottó   Hammarström Lennart  

International Immunology, Vol. 18, Iss. 4, 2006-04 ,pp. : 525-536

Oxford University Press

Access to resources Recommend Favorite

Use of recombinant human erythropoietin in kidney transplant patients with stable graft function

By Ortiz F.   Guirado L.   Diaz J.   Garcia-Trabanino R.   Garra N.   Sainz Z.   Picazo M.   Garcia R.M.   Alcaraz A.   Sola R.  

Transplantation Proceedings, Vol. 35, Iss. 5, 2003-08 ,pp. : 1767-1768

Elsevier

Access to resources Recommend Favorite

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease

By Petkova Stefka B.   Akilesh Shreeram   Sproule Thomas J.   Christianson Gregory J.   Al Khabbaz Hana   Brown Aaron C.   Presta Leonard G.   Meng Y. Gloria   Roopenian Derry C.  

International Immunology, Vol. 18, Iss. 12, 2006-12 ,pp. : 1759-1769

Oxford University Press

Access to resources Recommend Favorite

Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation

By Baron F.   Sautois B.   Baudoux E.   Matus G.   Fillet G.   Beguin Y.  

Experimental Hematology, Vol. 30, Iss. 6, 2002-06 ,pp. : 546-554

Elsevier

Access to resources Recommend Favorite

Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study

By Abdelrazik Nabil   Fouda Manal  

Hematology, Vol. 12, Iss. 6, 2007-12 ,pp. : 533-541

Maney Publishing

Access to resources Recommend Favorite